Breastfeeding After Hormone Receptor–Positive Breast Cancer: Results From the POSITIVE Trial
Journal of Clinical Oncology · 2025
DOI: 10.1200/jco-24-02697 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Fedro A Peccatori und 35 weiteren Autor:innen. Beteiligte Einrichtung: Fertility and Procreation Unit, Gynecologic Oncology Program, European Institute of Oncology IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Breast Feeding. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Themen: Hebammenwesen und Geburtshilfe, Stillen
Abstract (Originalsprache)
PURPOSE We investigated breastfeeding patterns, behaviors, and association with breast cancer (BC) outcomes in women with early hormone receptor–positive (HR+) BC who had a live birth in the POSITIVE trial. PATIENTS AND METHODS POSITIVE is a prospective trial that demonstrated no increased short-term risk of BC events in women with early HR+ BC who interrupted endocrine therapy (ET) to attempt pregnancy. We describe the frequency, duration, and laterality of breastfeeding and estimate the cumulative incidence of BC events by breastfeeding status. RESULTS At a median follow-up of 41 months, 317 patients had at least one live birth and 313 were eligible for this analysis. A total of 196 of 313 (62.6%) patients breastfed. A total of 130 of the 167 women (77.8%) who had breast-conserving surgery breastfed, and 90 of 130 (69.2%) breastfed from the unaffected breast only. Sixty-six of the 146 women (45.2%) who underwent unilateral mastectomy breastfed. The frequency of breastfeeding was higher in women older than 35 years (67.6% v 55.7%) and in those without previous children (66.4% v 48.5%). Over half (103 of 196, 52.6%) of women breastfed their first live birth for >4 months (median 4.4 months; 95% CI, 4.0 to 5.3). The cumulative incidence of a BC event at 24 months from first on-study live birth was 3.6% and 3.1% in the breastfeeding and nonbreastfeeding groups, respectively (0.5% difference; 95% CI, –4.3% to 5.2%). CONCLUSION In POSITIVE, two thirds of women who gave birth after BC diagnosis breastfed, mostly for 4 months or more. In early follow-up, we did not observe differences in BC-related events in women who breastfed compared with those who did not. These results are key for women who wish to pursue pregnancy and breastfeeding after BC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Fertility and Procreation Unit, Gynecologic Oncology Program, European Institute of Oncology IRCCS, Milan, Italy.
- International Breast Cancer Study Group Statistical Center, Boston, MA.
- Division of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.
- Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
- Harvard Medical School, Boston, MA.
- Program for Young Patients, International Breast Cancer Study Group, A Division of ETOP IBCSG Partners Foundation, Bern, Switzerland.
ORCID-Profile: Fedro A Peccatori, Samuel M Niman, Ann H Partridge, Monica Ruggeri, Marco Colleoni, Cristina Saura, Chikako Shimizu, Judith R Kroep, Karen Gelmon, Frederic Amant, Audrey Mailliez, Halle C F Moore, Manuel Ruiz-Borrego, Janice M Walshe, Virginia F Borges, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Junko Takei, Jeong E Lee, Christobel Saunders, Snezana Susnjar, Fatima Cardoso, Natalie J Klar, Teresa Ferreiro, Sarra El-Abed, Martine Piccart, Richard D Gelber, Hatem A Azim
Förderung
- NCI NIH HHS
Zitieren
APA
Peccatori, F. A., Niman, S. M., Partridge, A. H., Ruggeri, M., Colleoni, M., Saura, C., Shimizu, C., Satersdal, A. B., Kroep, J. R., Gelmon, K., Amant, F., Mailliez, A., Moore, H. C. F., Ruiz-Borrego, M., Walshe, J. M., Borges, V. F., Gombos, A., Kataoka, A., Rousset-Jablonski, C., …, & International Breast Cancer Study Group and the POSITIVE Trial Collaborators (2025). Breastfeeding After Hormone Receptor–Positive Breast Cancer: Results From the POSITIVE Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-02697
Vancouver
Peccatori FA, Niman SM, Partridge AH, Ruggeri M, Colleoni M, Saura C, et al. Breastfeeding After Hormone Receptor–Positive Breast Cancer: Results From the POSITIVE Trial. Journal of Clinical Oncology. 2025. doi:10.1200/jco-24-02697
BibTeX
@article{Peccatori2025,
author = {Peccatori, Fedro A and Niman, Samuel M and Partridge, Ann H and Ruggeri, Monica and Colleoni, Marco and Saura, Cristina and Shimizu, Chikako and Satersdal, Anna B and Kroep, Judith R and Gelmon, Karen and Amant, Frederic and Mailliez, Audrey and Moore, Halle C F and Ruiz-Borrego, Manuel and Walshe, Janice M and Borges, Virginia F and Gombos, Andrea and Kataoka, Akemi and Rousset-Jablonski, Christine and Borstnar, Simona and Takei, Junko and Lee, Jeong E and Saunders, Christobel and Bjelic-Radisic, Vesna and Susnjar, Snezana and Cardoso, Fatima and Klar, Natalie J and Ferreiro, Teresa and El-Abed, Sarra and Piccart, Martine and Korde, Larissa A and Goldhirsch, Aron and Gelber, Richard D and Pagani, Olivia and Azim, Hatem A and International Breast Cancer Study Group and the POSITIVE Trial Collaborators, International Breast Cancer Study Group and the POSITIVE Trial Collaborators},
title = {Breastfeeding After Hormone Receptor–Positive Breast Cancer: Results From the POSITIVE Trial},
journal = {Journal of Clinical Oncology},
year = {2025},
doi = {10.1200/jco-24-02697}
}
EUVIMED